WCN26-7745 EFFICACY OF DESIDUSTAT IN ERYTHROPOIETIN-HYPORESPONSIVE CKD PATIENTS: A REAL-WORLD EVALUATION AS PER KDIGO GUIDELINES

Read full text Summarise with VIRAT
Authors: Himanshu Verma, Sourabh Sharma, Anupam Agarwal, Pallavi Prasad
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Erythropoietin (EPO) hyporesponsiveness continues to challenge anemia management in patients with chronic kidney disease (CKD), despite adherence to KDIGO-recommended dosing strategies. Persistent anemia in such cases often warrants exploration of alternative therapeutic options. Desidustat, an oral hypoxia-inducible factor–prolyl hydroxylase inhibitor (HIF-PHI), stimulates endogenous erythropoietin production and enhances iron utilization. This study evaluated the hematologic response and biochemical safety of Desidustat in EPO-hyporesponsive CKD patients undergoing dialysis.

Fields of Study & Subjects

Erythropoietin and Anemia Treatment Dialysis and Renal Disease Management Iron Metabolism and Disorders

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104269–104269
Publication date
25 March 2026
Language
EN